About RevOpsis Therapeutics
RevOpsis Therapeutics is a private company based in Springfield, Illinois, incorporated in 2022 in Delaware. It has reported $8,570,004 raised in four offerings on Form D since July 2022. Its chief executive is Ramanath Bhandari.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 24, 2024 | Nov 7, 2024 | $575,000target not set | 4 | $143K | SAFE (Simple Agreement for Future Equity)Rule 506(b) | Form D ↗ |
| Jul 26, 2023 | Aug 10, 2023 | $7,895,004fully sold | 36 | $219K | EquityRule 506(c) | Form D ↗ |
| Aug 19, 2022 | Aug 24, 2022 | $100,000of $18.0M target | 1 | $100K | Simple Agreement for Future EquityRule 506(c) | Form D ↗ |
| Mar 22, 2022 | Jul 29, 2022 | $0of $521K target | 4 | $0 | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $8,570,004 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on RevOpsis Therapeutics's Form D filed Nov 7, 2024.
RB
Ramanath Bhandari
Chief Executive Officer
RP
Ram Palanki
Director
Earlier filings also listed Jeff Olson (director, last listed Aug 2022).